Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to evaluate the effect of additional estradiol estrogen therapy on clinical response and mortality in non-severe COVID-19 patients
Actually, there is not treatment or vaccine that can prevent or control the evolution of COVID-19. The epidemiological data reported in China by the Center for Disease Control (CDC) on February 2020, reported that 87% of the patients have been adults in an age range of 30-69 years. In addition, different studies have shown that male gender are more vulnerable for the contagion of the virus (60%-80%), as well as the clinical evolution of COVID-19 (including mortality) compared to the female sex (20-40%), independently of individual such as diabetes, cardiovascular diseases, obesity, mainly.
The mechanism of SARS-CoV-2 infection has been shown to occur with the interaction of angiotensin converting enzyme 2 (ACE2), this enzyme is expressed in lungs, brain, heart, kidneys and gastrointestinal tract. Also, has been shown that older people have higher levels of ACE2 expression. Among the different molecular functions of ACE2 are the regulation of cell proliferation, cytokine production, and inflammatory response.
It has been proposed that exogenous human recombinant ACE2 could be an alternative treatment for COVID-19, however, this treatment is not yet highly available and could entail high costs. Other molecules as estrogens have been proposed in different research groups, for its capacity to increase the gene expression of ACE2/Ang 1-7. This mechanism could reduce lung and endothelial damage and coagulopathy in COVID-19 patients.
So, it is relevant to evaluate the effect of additional estradiol estrogen (as adjuvant therapeutic element) therapy on clinical response and mortality in non-severe COVID-19 patients.
A controlled clinical trial will be conducted in a tertiary hospital in Mexico City, Mexico. Participants will be divide in two groups; 1) intervention: who will receive EVRA skin patches (1 patch every week during 21 days) with norelgesetromin 6mg / ethinyl estradiol 0.60mg and 2) control: who will receive conventional treatment
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Estrogen Therapy | Experimental | Drug: Norelgesetromin 6mg / Ethinyl estradiol 0.60mg Dosage form: EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days) |
|
| Control Group | No Intervention | Patients who will receive conventional COVID-19 treatment |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Estrogen Therapy | Drug | EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Clinical improve to estrogen therapy in non-severe COVID-19 patients Clinical improve to estrogen therapy in non-severe COVID-19 patients |
| Day 7 |
| Clinical improve to estrogen therapy in non-severe COVID-19 patients |
| Day 14 |
| Clinical improve to estrogen therapy in non-severe COVID-19 patients |
| Day 21 |
| Measure | Description | Time Frame |
|---|---|---|
| Symptomatic improve to estrogen therapy in non-severe COVID-19 patients | According to the National Committee for Epidemiological Surveillance (CONAVE) in Mexico, COVID-19 symptomatic onset rate defined as the presence of cough, fever or headache during the last 7 days, accompanied at least one of the following symptoms: dyspnea, arthralgia, myalgia, odynophagia / pharyngeal burning, rhinorrhea, conjunctivitis or chest pain. |
Not provided
Inclusion Criteria:
Male ≥ 18 years of age and female ≥ 55 years of age
Diagnosis of positive SARS-CoV-2 infection confirmed by clinical diagnosis and / or RT-PCR test
Hospitalized patients in acute disease* stages of the disease
Agree to participate in the study prior to signing an informed consent.
Patients with conventional treatment with anticoagulants (Noxaparin)
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rodrigo Ruz Barros, MD | CMN "20 de Noviembre" | Study Chair |
| Daniel Santillán Cortés, MSc | CMN "20 de Noviembre" | Study Chair |
| Mónica Escamilla Tilch, PhD | CMN "20 de Noviembre" | Study Chair |
| Juan A Pineda Juárez, PhD | CMN "20 de Noviembre" | Study Chair |
| Sandra Muñoz López, MD | CMN "20 de Noviembre" | Study Chair |
| Maricela Escarela Serrano, MD | CMN "20 de Noviembre" | Study Chair |
| Paul Mondragón Terán, PhD | CMN "20 de Noviembre" | Study Chair |
| Alberto H De la Vega Bravo, MD | CMN "20 de Noviembre" | Study Chair |
| Alfredo L Cortés Algara, MD, MSc | CMN "20 de Noviembre" | Principal Investigator |
| Samuel Reyes-Long, MSc | Neurociencias básicas, Instituto Nacional de Rehabilitación LGII |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CMN "20 de Noviembre" | Mexico City | Benito Juárez | 03100 | Mexico |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D015914 | Estrogen Replacement Therapy |
| D004997 | Ethinyl Estradiol |
| ID | Term |
|---|---|
| D020249 | Hormone Replacement Therapy |
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
| D009651 | Norpregnatrienes |
Not provided
Not provided
Not provided
Not provided
Not provided
The Outcome Assessor will be an external member of the Gynecology Service, which will be blinded to the intervention.
| Day 7 |
| Symptomatic improve to estrogen therapy in non-severe COVID-19 patients | According to the National Committee for Epidemiological Surveillance (CONAVE) in Mexico, COVID-19 symptomatic onset rate defined as the presence of cough, fever or headache during the last 7 days, accompanied at least one of the following symptoms: dyspnea, arthralgia, myalgia, odynophagia / pharyngeal burning, rhinorrhea, conjunctivitis or chest pain. | Day 14 |
| Symptomatic improve to estrogen therapy in non-severe COVID-19 patients | According to the National Committee for Epidemiological Surveillance (CONAVE) in Mexico, COVID-19 symptomatic onset rate defined as the presence of cough, fever or headache during the last 7 days, accompanied at least one of the following symptoms: dyspnea, arthralgia, myalgia, odynophagia / pharyngeal burning, rhinorrhea, conjunctivitis or chest pain. | Day 21 |
| Biochemical improve to estrogen therapy in non-severe COVID-19 patients | Percentage change from hemoglobin, hematocrit, leukocytes, erythrocytes, platelets, prothrombin, partial thromboplastin activation time, anti-thrombin activity, fibrinogen, fibrin degradation products, D-Dimer, ALT, AST, ALP, GGT, LD, albumin, cholesterol, triglycerides, HDL, LDL, C-reactive protein, estrogens and progesterone levels, pro inflammatory cytokine and nitric oxide profile. | Day 7 |
| Biochemical improve to estrogen therapy in non-severe COVID-19 patients | Percentage change from hemoglobin, hematocrit, leukocytes, erythrocytes, platelets, prothrombin, partial thromboplastin activation time, anti-thrombin activity, fibrinogen, fibrin degradation products, D-Dimer, ALT, AST, ALP, GGT, LD, albumin, cholesterol, triglycerides, HDL, LDL, C-reactive protein, estrogens and progesterone levels, pro inflammatory cytokine and nitric oxide profile. | Day 14 |
| Angiotensin 1-7 change after estrogen therapy in non-severe COVID-19 patientsCOVID-19 patients | Percentage change from Angiotensin 1-7, measured with the Human Angiotensin 1-7 ELISA kit (colorimetric) [pg/mL] | Day 21 |
| Study Chair |
| Cindy Bandala, MD MSc PhD | Neurociencias básicas, Instituto Nacional de Rehabilitación LGII; Escuela Superior de Medicina, Instituto Politécnico Nacional | Study Chair |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D009650 |
| Norpregnanes |
| D009654 | Norsteroids |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D042782 | Estrogenic Steroids, Alkylated |
| D045166 | Estradiol Congeners |
| D012739 | Gonadal Steroid Hormones |
| D042341 | Gonadal Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |